AzTrials
AzTrials

CancerACE-NeuroNCT04831190

A Tailored Exercise Oncology Program for Neuro-Oncology Patients

A study testing Tailored Exercise Intervention in people with Cancer and Brain Tumor, Primary, run by University of Calgary at 4 sites in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: Exercise, or physical activity, is beneficial for all cancer survivors. Despite this knowledge, there is generally a gap between the evidence and practice. And this gap is widened with (a) underserved tumour groups in exercise oncology, such as neuro-oncology patients, or (b) underutilized timelines across… Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
Conditions the study is for
Cancer, Brain Tumor, Primary
What is being tested?
Tailored Exercise Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
4 sitesCanada
Study dates
15 Apr 2021to 15 Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • are a neuro-oncology patient with primary brain tumour (malignant or benign)
  • are pre-, on, or completed treatment
  • are over the age of 18 years
  • are able to read/write in English
  • are able to participate in mild levels of exercise
  • are able to access remote programming (i.e., has internet access and a computer or tablet)

Who cannot join

  • diagnosis is not primary brain
  • unable to read/write in English
  • are unable to participate in light exercise
  • for online programs, do not have internet or computer access

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • Health and Wellness Lab, University of Calgary

    Calgary, Alberta, T2N 1N4

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2

  • Cross Cancer Institute, University of Alberta

    Edmonton, Alberta, T6G 1Z2

  • Cancer Rehabilitation Clinic, Faculty of Rehabilitation Medicine, University of Alberta

    Edmonton, Alberta, T6G 2G4

Other trials in Canada

About this study

Official title: ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients

Background: Exercise, or physical activity, is beneficial for all cancer survivors. Despite this knowledge, there is generally a gap between the evidence and practice. And this gap is widened with (a) underserved tumour groups in exercise oncology, such as neuro-oncology patients, or (b) underutilized timelines across the cancer treatment phases to deliver exercise oncology education or programming. Thus, our current work is building a hybrid implementation effectiveness study into the clinical care pathway across Alberta in neuro-oncology - ACE-Neuro.

Objectives: The purpose of this study is to assess the impact of an online, tailored exercise oncology program for neuro-oncology patients using a participant-oriented research (POR) approach as well as both quantitative and qualitative research methods. Specifically, the primary outcome of this study is to determine the feasibility of recruitment, referral, triage, adherence, and adverse events. The secondary outcome is to examine the preliminary effectiveness of the neuro-oncology exercise program on patient-reported outcomes and physical function.

Read more

Methods: Neuro-oncology patients >18 years and able to consent in English will be referred to a study-based Rehabilitation Triage Clinic, where a Physician-Researcher will assess patients on their overall health and functional status, and next triage them to either ACE-Neuro, rehabilitation oncology, or cancer physiatry. Once referred to ACE-Neuro, participants will partake in a 12-week online exercise program, delivered by a Clinical Exercise Physiologist. Participants will complete online assessments of physical function, patient-reported outcomes, and objective physical activity at baseline (pre-program), 12-weeks (post-program completion), 6-months, and 12-months. The exercise program includes weekly one-on-one online exercise delivery, health coaching to support behaviour change, and access to an online group exercise session. Participants will also be invited to a post-program qualitative interview to get perspectives on their experiences participating in ACE-Neuro.

Relevance: By working directly with patients, healthcare providers, and community partners, this implementation project will develop a framework that streamlines patient triage, and provides a tailored online exercise program for neuro-oncology patients, thereby advancing exercise oncology research and clinical practice.

Read the detailed description

BACKGROUND \& RATIONALE

Exercise, or physical activity, is beneficial for all cancer survivors. Despite this knowledge, there is generally a gap between the evidence and practice. And this gap is widened with (a) underserved tumour groups in exercise oncology, such as neuro-oncology patients, or (b) underutilized timelines across the cancer treatment phases to deliver exercise oncology education or programming.

Within Alberta (AB), the investigators have been able to very successfully implement the Alberta Cancer Exercise (ACE) program to start to address the gap between research and practice. As a hybrid implementation effectiveness study, ACE is building a model for exercise oncology delivery within standard cancer care. With over 2500 participants across AB, the investigators have substantial evidence supporting the feasibility of ACE, as well as the potential benefits. Despite these successes, ACE remains primarily represented by participants from breast, prostate, and colorectal tumour groups. This represents a lack of connection between smaller and more high risk tumour groups within referral pathways for the ACE program, both at TBCC and CCI, but also within the regional community cancer clinics (Grande Prairie, Red Deer, Medicine Hat, Lethbridge).

RESEARCH QUESTION \& OBJECTIVES

The purpose of this feasibility-implementation study is to build exercise into the clinical care pathway in neuro-oncology clinics at the two major cancer centres in AB, where all neuro-oncology patients provincially are treated (Tom Baker Cancer Centre, TBCC; and the Cross Cancer Institute, CCI). Specifically, the objectives of the proposed work are: (1) to tailor the ACE exercise program for all neuro- oncology patients, to ACE-Neuro; this includes considering additional tailoring to address needs earlier in the care pathway, from diagnosis through treatment (i.e., prehabilitation phases) and into longer term survivorship (wellness cancer survivorship care plans), (2) to provide models of delivery of exercise oncology programs to enhance access (i.e., remote delivery, home support, individual vs group), and (3) to build this systematically within the neuro-oncology clinics at the TBCC and CCI, to ensure that all patients diagnosed with brain tumours can access wellness during their cancer care journey. The investigators hypothesize that there will be improvements in patients' physical and psychosocial well-being (individual level outcomes), as well as a more integrated workflow in the clinical cancer care setting that includes exercise as part of standard clinical practice (systems level outcome). Specifically, the primary outcome of this study is to determine the feasibility of recruitment, referral, triage, adherence, and adverse events. The secondary outcome is to examine the preliminary effectiveness of the neuro-oncology exercise program on patient-reported outcomes and physical function.

METHODS

Using the successful implementation model developed in ACE, the proposed work will build a neuro-oncology cohort within a mixed methods study design. There will be multiple phases to the implementation of ACE-Neuro, including:

  1. Building awareness within the clinical teams, identifying site champions, and providing educational and referral resources specific to neuro-oncology and exercise;
  2. Working with neuro-oncology patients and families to develop the unique aspects of exercise programming (from "move more" programs to "exercise") to address identified needs. This co-creation process will also include the cancer physiatry team (Dr. George Francis, Dr. Lauren Capozzi) and the clinical neuro-oncology teams (Dr. Gloria Roldan Urgoiti at TBCC and Dr. Jay Easaw at CCI) to address medical clinical needs that can be addressed within the ACE-Neuro program, and clinical workflow logistics with physiatry and physiotherapy to address specific treatment-related side effects (such as limb weakness, balance, or cognitive function);
  3. implementation of the ACE-Neuro tailored program, including referral, screening, assessments, intervention delivery, and follow-ups. Details of the ACE-Neuro procedures are detailed below.

REFERRAL AND RECRUITMENT

Because the main outcome of this study is feasibility, and the ultimate goal is to build ACE-Neuro into standard neuro-oncology care, no a priori sample size has been calculated. Based on current clinical numbers, and previous work done with neuro-oncology patients at CCI, the investigators anticipate approximately 25-30 eligible patients per year, per site. Our aim is to referral of all eligible neuro-oncology patients from TBCC. For recruitment, patients can:

  1. self-refer (i.e. patient contacts the study team from a poster or brochure received in clinic, through word of mouth); OR study team can refer:
  2. clinical team sends referral to rehab oncology via Putting Patients First Questionnaire (via ARIA).

The clinical team, based on their judgment, may not refer patients they deem to be ineligible. This may include for the following reasons:

  1. Patient is not interested when exercise idea is brought up.
  2. Health care provider deems patient clinically ineligible, due to disease progression, end-of-life care, or other health factor
  3. Patient does not speak English
  4. Other

As a feasibility study, reasons for non-referral will be tracked, with no identifying patient information, across the recruitment period. After consenting to the study, all patients will undergo a two-part screening procedure prior to beginning the exercise program:

  1. Patients will complete health and medical history screening using the Health History Questionnaire, Identifying Information Questionnaire, and the Physical Activity Readiness Questionnaire; PAR-Q.
  2. Patients will attend a Neuro Oncology Rehabilitation Triage Clinic, led by a Resident Physician (Dr. Lauren Capozzi; supervised by Dr. George Francis) and the ACE-Neuro Study Coordinator (Julia Daun). During this 30-minute appointment, patients will complete the Short Physical Performance Battery screening test6, and a full neurological exam, including Karnofsky performance and Eastern Cooperative Oncology Group (ECOG) scores. This appointment will assess the patients' readiness for participating in ACE-Neuro.

As part of this study, the investigators will be tracking the referral pathway, and which method of referral is most feasible as part of standard clinical workflow.

ASSESSMENTS

  1. Patient-Reported Outcomes (PROs) - will include symptom burden (Edmonton Symptom Assessment Scale-Revised; ESAS-r), PA levels (Godin Leisure Time Exercise Questionnaire-Modified; GLTEQ), quality of life (Functional Assessment of Cancer Therapy-Brain; FACT-Br), cognitive function (Functional Assessment of Cancer Therapy-Cognitive Scale; FACT-Cog), and fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue; FACIT-F).
  2. Functional Fitness Assessments - will follow the set protocols within ACE (HREBA-CC-16- 0905_MOD12), and are designed to be able to be completed in-person or via remote delivery (online assessment). All fitness assessments will be completed by a Clinical Exercise Physiologist and will include the assessment of lower body strength and endurance (30-second sit-to-stand), static balance (single leg stance), flexibility (sit-and-reach and active shoulder flexion), and cardiorespiratory fitness (2-minute step test or 6MWT).
  3. Objective Physical Activity - will be measured via the use of a wrist-worn activity tracker (WAT; i.e., Garmin vivosmart® 4). Garmin wearable PA trackers are widely used across health research, and will be provided to all participants to objectively track PA habits throughout the intervention.
  4. Qualitative Interviews and Photo Elicitation: Qualitative data will be gathered across the co-creation process via interviews and photo elicitation, to inform the feasibility of ACE-Neuro, as well as to assess outcomes associated with participation in the ACE-Neuro program (benefits, barriers, satisfaction, impact on well-being). Qualitative data will be stored on a secure server.

HEALTH COACHING

In addition to exercise delivery and assessments, all participants will have the choice to participate in evidence-based health coaching calls, provided by a trained Health Coach. Health coaching is an evidence-based tool that supports positive health behaviour change across cancer populations. Health coaching calls will take place weekly for 15-30 minutes following an individualized exercise training session, and include topics surrounding goal setting, social support, stress management, maintaining motivation, and overcoming barriers. Health coaching calls will be delivered remotely (e.g., via end-to-end encrypted Zoom or phone call) at the participants' preferred date and time.

TIMELINE

The described exercise program and data collection of PROs and functional fitness assessments are in addition to standard practices. The timeline for these assessments include: baseline (at recruitment into ACE-Neuro), 12-weeks (post-intervention), 6-months, and 12-months.

ANALYSIS Quantitative analysis will include descriptive statistics (means, medians, standard deviations), and change scores to measure changes in outcomes over time. Qualitative data will be analyzed by verbatim transcription (in NVivo), using an interpretive description methodology. Both quantitative and qualitative data will be analyzed to provide a deeper understanding of the feasibility and impact of ACE-Neuro.

RELEVANCE By working directly with patients, healthcare providers, and community partners, this implementation project will develop a framework that streamlines patient triage, and provides a tailored online exercise program for neuro-oncology patients, thereby advancing exercise oncology research and clinical practice.

Being tested
Tailored Exercise Intervention
Keywords
Neuro-Oncology, Cancer, Exercise, Quality of Life, Feasibility, Implementation
Medical subject headings
Neoplasms, Brain Neoplasms, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tailored Exercise InterventionBehavioural

    The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.

Study groups in NCT04831190
Study groupRoleWhat they receive
InterventionExperimentalAll participants will be involved in a tailored exercise intervention for 12 weeks.
Receives: Behavioral: Tailored Exercise Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of Referral: Referral Rate

    The percentage of patient referrals to the study team from the clinical team from patients eligible.

    Measured: From start of study recruitment to end of study (2 years).

  2. Feasibility of Enrolment: Enrolment Rate

    The percentage of patients that enrol in the study once they hear the full study introduction.

    Measured: From start of study recruitment to end of study (2 years).

  3. Feasibility of Triage: Triage Completion Rate

    The percentage of participants that attend, from those that are referred, to the Neuro-Oncology Rehabilitation Triage Clinic.

    Measured: From start of study recruitment to end of study (2 years).

  4. Feasibility of Program Attendance: Program Attendance Rate

    Percentage of classes attended by enrolled participants.

    Measured: Baseline to 12 weeks.

  5. Feasibility of Measurement Completion: Measurement Completion Rate (Baseline)

    Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.

    Measured: At baseline (0 weeks).

  6. Feasibility of Measurement Completion: Measurement Completion Rate (12 Weeks)

    Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.

    Measured: Post-program completion (12 weeks).

  7. Feasibility of Measurement Completion: Measurement Completion Rate (6 Months)

    Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.

    Measured: At 6 months post study enrolment.

  8. Feasibility of Measurement Completion: Measurement Completion Rate (12 Months)

    Percentage of measures (i.e., patient-reported outcomes and physical function) completed by enrolled participants.

    Measured: At 12 months post study enrolment.

  9. Safety of Intervention

    Record of any adverse events related to the intervention.

    Measured: Baseline to 12 weeks.

  10. Attrition Rate

    Number of participants who consent but do not complete the intervention.

    Measured: Baseline to 12 weeks.

  11. Qualitative Feasibility: Qualitative Semi-Structured One-on-One Interviews

    Participant perception of intervention feasibility via semi-structured one-on-one interviews (qualitative data, not reported on a scale).

    Measured: Conducted between weeks 12-14.

Secondary outcomes (15)
  1. Physical Activity Minutes Per Week

    Change in number of participants meeting Guidelines for Physical Activity of 90 minutes per week of moderate intensity exercise, based on accelerometer data from commercially-available activity tracker (Garmin vivosmart® 4).

    Measured: Baseline to 12 weeks.

  2. Weekly Step Count

    Total weekly step count based on data from commercially-available activity tracker (Garmin vivosmart® 4).

    Measured: Baseline to 12 weeks.

  3. Body Composition

    Measure of change in body mass index (BMI) over time.

    Measured: Baseline to post 12-week exercise intervention.

  4. Cardiorespiratory Fitness

    Change in 6-minute walk test (m) or 2-minute step test (steps) results.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  5. Muscular Strength

    Change in hand-grip dynamometry (kg).

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  6. Muscular Endurance

    Change in sit-to-stand (number of repetitions in 30 seconds).

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  7. Upper Extremity Flexibility

    Change in active shoulder flexion range of motion (degrees).

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  8. Lower Extremity Flexibility

    Change in sit-and-reach test (cm).

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  9. Static Balance

    Change in one single-leg-stance test (seconds).

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  10. Symptom Burden

    Change in Edmonton Symptom Assessment Scale. Scale includes 10 questions total and is from 0-10, where 0 means the symptom is absent and 10 means the worst possible severity of the symptom is being experienced. Total score 0-100, higher is worse.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  11. Subjective Reporting of Average Weekly Physical Activity

    Change in Godin Leisure Time Exercise Questionnaire (GLTEQ). Self-reported as total minutes of physical activity in the past week. Calculated as [mild frequency per week x 3] + [moderate frequency per week x 5] + [strenuous frequency per week x 9]. Minimum score is 0, the maximum is dependent on the participant's frequency of physical activity. Higher score indicates more physical activity.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  12. Fatigue

    Change in Functional Assessment of Chronic Illness Therapy - Fatigue subscale Scale is from 0-4, where 0 means "not at all" and 4 means "very much". Total score 0-52, higher score is lower fatigue severity.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  13. Quality of Life - Brain Subscale

    Change in Functional Assessment of Cancer Therapy - Brain Subscale. Scale is from 0-4, where 0 means "not at all" and 4 means "very much". Total score ranges from 0-200. A higher score indicates a better outcome.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  14. Cognition

    Change in Functional Assessment of Cancer Therapy - Cognitive Subscale. Scale is from 0-4, where 0 means "never" and 4 means "several times a day" (experiencing symptoms). Total score ranges from 0-80. A higher score indicates a better outcome.

    Measured: Baseline to post 12-week exercise intervention and maintenance of change from 12-weeks to 6-months; and from 12 weeks to 12 months.

  15. Program Implementation and Evaluation

    The RE-AIM Framework: program reach, effectiveness, adoption, implementation and maintenance.

    Measured: Baseline to 2 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Apr 2021
  2. Study start15 Apr 2021
  3. Primary completion2 Dec 2022
  4. Study completion15 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Model description
Feasibility-Implementation Study
Masking
None (open label)
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04831190
Sponsor's protocol ID
HREBA.CC-20-0322
Acronym
ACE-Neuro
Status last verified
Jan 2023
First submitted
1 Apr 2021
Last updated
18 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No plan at this time to share IPD outside of the research team.

Publications

  • Daun JT, Roldan Urgoiti G, Bansal M, McDonough MH, Capozzi LC, Easaw JC, McNeely ML, Francis GJ, Culos-Reed SN. One step forward, two steps back: a qualitative study of clinical perspectives on implementing exercise in neuro-oncology care. J Cancer Surviv. 2026 Sep 2. doi: 10.1007/s11764-026-02113-2. Online ahead of print.

    PubMed 42684658
  • Daun JT, Capozzi LC, Dhruva T, Roldan Urgoiti G, McDonough MH, McLaughlin E, Bansal M, Brett A, Easaw JC, McNeely ML, Francis GJ, Williamson T, Danyluk J, Ospina PA, Lesiuk C, de Robles P, Leckie C, Culos-Reed SN. The feasibility of a multi-site, clinic-supported, and tailored neuro-oncology exercise program. Neurooncol Pract. 2024 Oct 10;12(1):131-142. doi: 10.1093/nop/npae093. eCollection 2025 Feb.

    PubMed 39917754

Questions about this trial

What is this clinical trial studying?

A study testing Tailored Exercise Intervention in people with Cancer and Brain Tumor, Primary, run by University of Calgary at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of Referral: Referral Rate (time frame: From start of study recruitment to end of study (2 years).). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04831190, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in